📊 CGTX Key Takeaways
Is Cognition Therapeutics Inc. (CGTX) a Good Investment?
CGTX is a pre-revenue/minimal-revenue stage biotech company with a strong balance sheet ($31.1M cash, no debt, excellent liquidity) providing approximately 18-24 months of operating runway. While the company shows improving loss metrics year-over-year, the absence of meaningful revenue combined with negative free cash flow of $5.5M quarterly presents significant execution risk typical of development-stage biologics companies.
Cognition Therapeutics has a clean balance sheet with substantial cash, minimal liabilities, and no meaningful debt, which supports near-term operating flexibility. However, the company remains essentially pre-revenue and deeply unprofitable, with negative operating cash flow and losses that are large relative to its equity base, so the fundamental story depends more on future clinical and commercialization execution than current business performance. The core fundamental profile is financially solvent but operationally weak, which supports a cautious stance.
Cognition Therapeutics Inc. Key Strengths (CGTX)
- Strong cash position of $31.1M with no long-term debt provides meaningful runway for R&D and clinical development
- Excellent liquidity ratios (5.92x current and quick ratios) indicate ability to meet near-term obligations
- Net loss improved 30.9% YoY despite minimal revenue, suggesting either improved cost structure or one-time positive items
- Lean capital expenditure profile ($4.0K) consistent with biotech R&D model
- Strong liquidity with $39.33M in cash and 6.44x current and quick ratios
- Very low leverage with no meaningful long-term debt and only $6.87M in total liabilities
- Low capital expenditure needs, preserving cash for R&D and operations
CGTX Stock Risks: Cognition Therapeutics Inc. Investment Risks
- Pre-revenue or near-zero revenue business model ($-10K) with no demonstrated commercial traction
- Negative operating cash flow of $5.5M quarterly with limited visibility to cash flow breakeven within runway
- Cash runway of only 18-24 months at current burn rate necessitates future capital raises or major operational milestones
- Biotech sector risk: clinical trial failures, regulatory setbacks, and development delays could rapidly deplete cash reserves
- 7 insider Form 4 filings in 90 days warrant monitoring for insider selling pressure
- Business is effectively pre-revenue, making growth quality and operating leverage very weak
- Large operating and net losses are driving negative ROE, negative ROA, and ongoing cash burn
- Cash runway could compress if operating cash outflows remain near current levels without meaningful revenue inflection
Key Metrics to Watch
- Quarterly cash burn rate and operating cash flow trajectory toward positive FCF
- Revenue generation and commercial stage progression of pipeline assets
- Cash position relative to runway; timing and terms of any future financing
- Operating expense control and R&D efficiency metrics relative to peer biotech companies
- Quarterly operating cash burn relative to cash balance
- Revenue progression and reduction in operating loss as pipeline programs advance
Cognition Therapeutics Inc. (CGTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 55,460.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.92x current ratio provides a solid financial cushion.
CGTX Profit Margin, ROE & Profitability Analysis
CGTX vs Healthcare Sector: How Cognition Therapeutics Inc. Compares
How Cognition Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cognition Therapeutics Inc. Stock Overvalued? CGTX Valuation Analysis 2026
Based on fundamental analysis, Cognition Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cognition Therapeutics Inc. Balance Sheet: CGTX Debt, Cash & Liquidity
CGTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cognition Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.86 indicates the company is currently unprofitable.
CGTX Revenue Growth, EPS Growth & YoY Performance
Cognition Therapeutics Inc. Dividends, Buybacks & Capital Allocation
CGTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cognition Therapeutics Inc. (CIK: 0001455365)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CGTX
What is the AI rating for CGTX?
Cognition Therapeutics Inc. (CGTX) has a Combined AI Grade of C from Claude (B) and ChatGPT (C) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CGTX's key strengths?
Claude: Strong cash position of $31.1M with no long-term debt provides meaningful runway for R&D and clinical development. Excellent liquidity ratios (5.92x current and quick ratios) indicate ability to meet near-term obligations. ChatGPT: Strong liquidity with $39.33M in cash and 6.44x current and quick ratios. Very low leverage with no meaningful long-term debt and only $6.87M in total liabilities.
What are the risks of investing in CGTX?
Claude: Pre-revenue or near-zero revenue business model ($-10K) with no demonstrated commercial traction. Negative operating cash flow of $5.5M quarterly with limited visibility to cash flow breakeven within runway. ChatGPT: Business is effectively pre-revenue, making growth quality and operating leverage very weak. Large operating and net losses are driving negative ROE, negative ROA, and ongoing cash burn.
What is CGTX's revenue and growth?
Cognition Therapeutics Inc. reported revenue of $-10.0K.
Does CGTX pay dividends?
Cognition Therapeutics Inc. does not currently pay dividends.
Where can I find CGTX SEC filings?
Official SEC filings for Cognition Therapeutics Inc. (CIK: 0001455365) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CGTX's EPS?
Cognition Therapeutics Inc. has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CGTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cognition Therapeutics Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CGTX stock overvalued or undervalued?
Valuation metrics for CGTX: ROE of -15.3% (sector avg: 15%), net margin of 45,700.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CGTX's AI grade for 2026?
Our dual AI analysis gives Cognition Therapeutics Inc. a combined C grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CGTX's free cash flow?
Cognition Therapeutics Inc.'s operating cash flow is $-5.5M, with capital expenditures of $4.0K. FCF margin is 55,460.0%.
How does CGTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 45,700.0% (avg: 12%), ROE -15.3% (avg: 15%), current ratio 5.92 (avg: 2).